ROLE OF CONTINUOUS GLUCOSE MONITORING IN DIABETIC NEUROPATHY

Dorin Ionescu; Daniela Stegaru Mihai; Andra Elena Balcangiu-Stroescu; Delia Timofte; Dorin Dragoș; Maria Daniela Tănăsescu; Ileana Adela Văcăroiu; Adrian Tulin; Ovidiu Știru; Anca Oprescu Macovei; Raluca Tulin; Doina Andrada Mihai

Dorin Ionescu Department of Medical Semiology, Discipline of Internal Medicine I and Nephrology, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of Nephrology, Bucharest Emergency University Hospital, Bucharest, Romania
Daniela Stegaru Mihai Discipline of Diabetes, Nutrition and Metabolic Diseases, “Carol Davila” University of Medicine and Pharmacy, Faculty of Medicine, Bucharest, Romania & “Nicolae Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania
Andra Elena Balcangiu-Stroescu Department of Dialysis, Bucharest Emergency University Hospital, Bucharest, Romania & Discipline of Physiology, Faculty of Dental Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Delia Timofte Department of Dialysis, Bucharest Emergency University Hospital, Bucharest, Romania
Dorin Dragoș Department of Medical Semiology, Discipline of Internal Medicine I and Nephrology, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of Internal Medicine I, Bucharest Emergency University Hospital, Bucharest, Romania
Maria Daniela Tănăsescu Department of Medical Semiology, Discipline of Internal Medicine I and Nephrology, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of Nephrology, Bucharest Emergency University Hospital, Bucharest, Romania
Ileana Adela Văcăroiu Department of Nephrology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Adrian Tulin Department of Anatomy, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of General Surgery, “Prof. Dr. Agrippa Ionescu” Clinical Emergency Hospital, Bucharest, Romania
Ovidiu Știru Department of Cardiovascular Surgery, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Anca Oprescu Macovei Department of Medical Semiology, Discipline of Internal Medicine I and Nephrology, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of Nephrology, Bucharest Emergency University Hospital, Bucharest, Romania
Raluca Tulin Department of Embryology, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Doina Andrada Mihai Discipline of Diabetes, Nutrition and Metabolic Diseases, “Carol Davila” University of Medicine and Pharmacy, Faculty of Medicine, Bucharest, Romania & “Nicolae Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania

Keywords: continuous glucose monitoring systems, diabetic neuropathy, glucose variability

Abstract

Diabetes is a major health problem due to its high prevalence and chronic complications that lead to disability and reduced quality of life. Among the complications, diabetic neuropathy, with its many forms, is the most common. Glycemic control plays a crucial role in the occurrence of chronic complications. Recently, with the advent of new technologies for continuous glycemic monitoring, the role of glycemic variability in the occurrence, progression, evaluation and treatment of chronic complications is increasingly understood. The widespread use of these technologies in clinical practice will optimize the care of patients with diabetes.

References

[1] P.J. Dyck, J.W. Albers, H. Andersen, J.C. Arezzo, G.J. Biessels et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev; vol 27, pp 620-628, April 2011.
[2] L. Ang, M. Jaiswal, C. Martin, R. Pop-Busui. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep, Vol 14, pp 528, January 2014.
[3] R. Pop-Busui, W.H. Herman, E.L. Feldman, P.A. Low, C.L. Martin, P.A. Cleary, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep; Vol 10, pp 276–282, March 2010.
[4] B. Sun, Z. Luo, J. Zhou. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovasc Diabetol; vol 20, pp 124-131, January 2021.
[5] B. Kovatchev, C. Cobelli. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care; vol 39, pp 502–510, Octomber 2016.
[6] T. Battelino, T. Danne, R.M, Bergenstal, S.A. Amiel, R. Beck, T. Biester, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care, vol 42, pp 1593-1603, June 2019.
[7] G.E. Umpierrez, B.P. Kovatchev. Glycemic Variability: How to Measure and Its Clinical Implication for Type 2. Diabetes Am J Med Sci 356(6):518-527, 2018.
[8] N. C. G Kwai, R. Arnold, A.M. Poynten, A.V. Krishnan. Association between glycemic variability and peripheral nerve dysfunction in type 1 diabetes. Muscle Nerve, vol 54, pp 967–969, July 2016.
[9] M. Akaza, I. Akaza, T. Kanouchi, T. Sasano, Y. Sumi, T. Yokota. Nerve conduction study of the association between glycemic variability and diabetes neuropathy. Diabetol Metab Syndr; vol 10, pp 69, May 2018.
[10] F. Li, Y. Zhang, H. Li, J. Lu, L. Jiang et al. TIR generated by continuous glucose monitoring is associated with peripheral nerve function in type 2 diabetes. Diabetes Res Clin Pract; vol 166, pp 108-115, February 2020.
[11] L. Mayeda, R. Katz, I. Ahmad, N. Bansal, Z. Batachhi et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care; vol 8, pp 84-92, September 2020.
[12] Y. Hu, L. Zhao, X. Zhang, H. Cai, H. Huang et al. Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients. Endocrine; vol 60, pp 292–300, June 2018.
[13] J. Yang, X. Yang, D. Zhao, X. Wang, W. Wei, H. Yuan. Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy. J Diabetes Investig; vol12, pp 828– 836, March 2021.
[14] S. Nyiratz, F. Pesei, A. Orosz, S. Coluzzi, O. Vági et al. Cardiovascular Autonomic Neuropathy and Glucose Variability in Patients with Type 1 Diabetes: Is There an Association? Front Endocrinol; vol 9, pp 174, November 2018.
[15] J.E. Jun, S.E. Lee, Y.B. Lee, Y.J. Ahn, G. Kim, Y.K. Hur et al. Continuous glucose monitoring de¦ned glucose variability is associated with cardiovascular autonomic neuropathy in type 1 diabetes. Diabetes Metab Res Rev, vol 35, pp 30-38, May 2019.
[16] S. Kalopita, S. Liatis, P. Thomakos, I.Vlahodimitris, C. Stathi, N. Katsilambros et al. Relationship between autonomic nervous system function and continuous interstitial glucose measurement in patients with type 2 diabetes. J Diabetes Res; vol 22, pp 127-135, Octomber 2014.
[17] J.E. Jun, S.M. Jin, J. Baek, S. Oh, Y.K. Hur, M.S. Lee, et al. The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes. Cardiovasc Diabetol; vol 4, pp 70, March 2015.
[18] Y. Kim, G. Kim, J.Y. Park, M.S. Choi, J.E. Jun et al. The Association Between Continuous Glucose Monitoring-derived Metrics, Including Time in Range, and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes. Research Square, vol 17, pp 172-183, May 2020.
[19] D. Matsutani, M. Sakamoto, H. Iuchi, S. Minato, H. Suzuki et al. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol; vol 17, pp 36, July 2018.
[20] C.A. van Beers, J.H. DeVries, S.J. Kleijer, M.M. Smits, P.H. Geelhoed-Duijvestijn, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol; vol 4, pp 893-902, September 2016.
[21] Y.K. Lin, S.J. Fisher, R. Pop-Busui. Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies. J Diabetes Investig; vol 11, pp 1388-1402, January 2020.